Cancer of the Bile Duct
5
1
2
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
9 treatments under study, led by Capecitabine
Research Leaders
6 sponsors active, led by H. Lee Moffitt Cancer Center and Research Institute
Related Conditions
Often studied with 20 related conditions
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
0.0%
0 terminated out of 5 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
100%
1 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (5)
A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)
Tempus Priority Study: A Pan-tumor Observational Study
Single Agent Regorafenib in Refractory Advanced Biliary Cancers
Self-expandable Metal Stents Versus Multiple Plastic Stents for Palliation of Biliary Obstruction
Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder Cancer
Research Network
Common Treatments
- Capecitabine1
- Oxaliplatin1
- Biliary Stent1
- Fluorouracil1
- Pembrolizumab1
Active Sponsors
- H. Lee Moffitt Cancer Center and Research Institute1
- National Cancer Institute (NCI)1
- Tempus AI1
- Bayer1
- University of Cape Town1
Top Investigators
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)
Tempus AI, Inc.
Related Conditions
- Cancer Of Larynx1
- Ovarian Cancer1
- Cancer Of Rectum1
- Peritoneal Cancer1
- Cancer Of Cervix1